$NNVC has developed NV-387, a revolutionary broad-spectrum antiviral, to address the urgent need for effective RSV treatment. Respiratory syncytial virus (RSV) poses significant health risks, particularly for infants and the elderly. Despite its prevalence, no approved therapeutic options exist for RSV, leaving patients vulnerable to severe complications.

Know more: http://tiny.cc/iulxzz